2,3-trimethylene-4-quinazolone has been researched along with Lung Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chatterjee, E; Dhingra, A; Grewal, AS; Guru, SK; Lee, SB; Liou, JP; Mathew, J; Nepali, K; Pan, CH; Rao, NV; Sharma, R; Sharma, S | 1 |
1 other study(ies) available for 2,3-trimethylene-4-quinazolone and Lung Neoplasms
Article | Year |
---|---|
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Hydrogen-Ion Concentration; Lung Neoplasms; Mice; Nanoparticle Drug Delivery System; Quinazolines; Quinazolinones | 2022 |